tiprankstipranks
Blurbs

Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Lantheus (LNTHResearch Report), Replimune Group (REPLResearch Report) and Intellia Therapeutics (NTLAResearch Report) with bullish sentiments.

Lantheus (LNTH)

SVB Securities analyst Roanna Ruiz maintained a Buy rating on Lantheus today and set a price target of $110.00. The company’s shares closed last Friday at $77.00, close to its 52-week high of $81.43.

According to TipRanks.com, Ruiz ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -56.7% and a 8.8% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as Enanta Pharmaceuticals, Xeris Pharmaceuticals, and Atea Pharmaceuticals.

Currently, the analyst consensus on Lantheus is a Strong Buy with an average price target of $100.33, which is a 40.3% upside from current levels. In a report released today, Truist Financial also maintained a Buy rating on the stock with a $100.00 price target.

See the top stocks recommended by analysts >>

Replimune Group (REPL)

SVB Securities analyst Jonathan Chang maintained a Buy rating on Replimune Group today and set a price target of $37.00. The company’s shares closed last Friday at $20.21.

According to TipRanks.com, Chang is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -12.5% and a 28.8% success rate. Chang covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Karyopharm Therapeutics, and Mersana Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Replimune Group with a $46.25 average price target.

Intellia Therapeutics (NTLA)

SVB Securities analyst Mani Foroohar maintained a Buy rating on Intellia Therapeutics today and set a price target of $152.00. The company’s shares closed last Friday at $61.34.

According to TipRanks.com, Foroohar is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -16.9% and a 38.4% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Recursion Pharmaceuticals, and 4D Molecular Therapeutics.

Currently, the analyst consensus on Intellia Therapeutics is a Strong Buy with an average price target of $108.33, which is a 71.5% upside from current levels. In a report released yesterday, Piper Sandler also maintained a Buy rating on the stock with a $163.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on LNTH:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More